{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T22:25:52Z","timestamp":1781562352525,"version":"3.54.5"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1007604","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000}}],"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"crossref","award":["292611, 279163, 295504, 310507, 326238"],"award-info":[{"award-number":["292611, 279163, 295504, 310507, 326238"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["ERA PerMed JAKSTAT-TARGET"],"award-info":[{"award-number":["ERA PerMed JAKSTAT-TARGET"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006383","name":"Cancer Society of Finland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006383","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1007604","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T13:33:31Z","timestamp":1580736811000},"page":"e1007604","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":69,"title":["SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy"],"prefix":"10.1371","volume":"16","author":[{"given":"Aleksandr","family":"Ianevski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanna","family":"Timonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kononov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-9769","authenticated-orcid":true,"given":"Tero","family":"Aittokallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0941-1458","authenticated-orcid":true,"given":"Anil K.","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,2,3]]},"reference":[{"issue":"8","key":"pcbi.1007604.ref001","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1128\/AAC.00474-11","article-title":"Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen","volume":"55","author":"S Ram\u00f3n-Garc\u00eda","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pcbi.1007604.ref002","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrclinonc.2016.96","article-title":"Combine and conquer: challenges for targeted therapy combinations in early phase trials","volume":"14","author":"JS Lopez","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"pcbi.1007604.ref003","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy","volume":"171","author":"AC Palmer","year":"2017","journal-title":"Cell"},{"issue":"5","key":"pcbi.1007604.ref004","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nrd3439","article-title":"Trial watch: Phase II failures: 2008\u20132010","volume":"10","author":"J Arrowsmith","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"pcbi.1007604.ref005","first-page":"93","article-title":"What is synergy","volume":"41","author":"MC Berenbaum","year":"1989","journal-title":"Pharmacol Rev"},{"key":"pcbi.1007604.ref006","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"CI Bliss","year":"1939","journal-title":"Ann Appl Biol"},{"issue":"6","key":"pcbi.1007604.ref007","first-page":"286","article-title":"The problem of synergism and antagonism of combined drugs","volume":"3","author":"S Loewe","year":"1953","journal-title":"ArzneimiettelForschung"},{"key":"pcbi.1007604.ref008","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Efficacy Model","volume":"13","author":"B Yadav","year":"2015","journal-title":"Comput Struct Biotechnol J"},{"issue":"16","key":"pcbi.1007604.ref009","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1080\/14656566.2017.1391216","article-title":"Cytarabine and daunorubicin for the treatment of acute myeloid leukemia","volume":"189","author":"T Murphy","year":"2017","journal-title":"Expert Opin Pharmacother"},{"issue":"22","key":"pcbi.1007604.ref010","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and Venetoclax for First-Line Treatment of CLL","volume":"380","author":"N Jain","year":"2019","journal-title":"N Engl J Med"},{"issue":"290","key":"pcbi.1007604.ref011","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa5597","article-title":"A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity","volume":"7","author":"LM Johansen","year":"2015","journal-title":"Sci Transl Med"},{"key":"pcbi.1007604.ref012","doi-asserted-by":"crossref","first-page":"S672","DOI":"10.1093\/infdis\/jiy304","article-title":"Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures","volume":"218","author":"J Dyall","year":"2018","journal-title":"J Infect Dis"},{"issue":"33","key":"pcbi.1007604.ref013","doi-asserted-by":"crossref","first-page":"53377","DOI":"10.18632\/oncotarget.10535","article-title":"Prexasertib,a Chk1\/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-\/T- cell progenitor acute lymphoblastic leukemia","volume":"7","author":"A Ghelli Luserna Di Ror\u00e0","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"pcbi.1007604.ref014","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/15563650.2010.495348","article-title":"Colchicine poisoning: the dark side of an ancient drug","volume":"48","author":"Y Finkelstein","year":"2010","journal-title":"Clin Toxicol (Phila)"},{"issue":"13","key":"pcbi.1007604.ref015","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2016-09-736892","article-title":"Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma","volume":"129","author":"S Gayle","year":"2017","journal-title":"Blood"},{"issue":"18","key":"pcbi.1007604.ref016","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"GY Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"issue":"15_suppl","key":"pcbi.1007604.ref017","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.1200\/JCO.2017.35.15_suppl.7544","article-title":"Phase I dose escalation of ibrutinib and buparlisib in relapsed\/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)","author":"CL Batlevi","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"pcbi.1007604.ref018","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/toxsci\/kft223","article-title":"A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans","volume":"137","author":"F Gustafsson","year":"2014","journal-title":"Toxicol Sci"},{"issue":"12","key":"pcbi.1007604.ref019","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1001\/jamainternmed.2016.6008","article-title":"Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results","volume":"176","author":"TJ Hwang","year":"2016","journal-title":"JAMA Intern Med"},{"key":"pcbi.1007604.ref020","article-title":"Genome-wide off-targets of drugs: risks and opportunities","author":"AK Giri","year":"2019","journal-title":"Cell Biol Toxicol"},{"issue":"15","key":"pcbi.1007604.ref021","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"SynergyFinder: a web application for analyzing drug combination dose-response matrix data","volume":"33","author":"A Ianevski","year":"2017","journal-title":"Bioinformatics"},{"issue":"4","key":"pcbi.1007604.ref022","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"5","author":"B Yadav","year":"2014","journal-title":"Sci Rep"},{"issue":"3","key":"pcbi.1007604.ref023","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/leu.2017.252","article-title":"Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling","volume":"32","author":"EI Andersson","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"pcbi.1007604.ref024","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1158\/0008-5472.CAN-17-3644","article-title":"Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients","volume":"78","author":"L He","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"pcbi.1007604.ref025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12943-016-0517-3","article-title":"Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells","volume":"15","author":"P Gautam","year":"2016","journal-title":"Mol Cancer"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1007604","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1007604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T01:26:19Z","timestamp":1695691579000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1007604"}},"subtitle":[],"editor":[{"given":"Manja","family":"Marz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,2,3]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1007604","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/693010","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,3]]}}}